Filtered By:
Condition: Atrial Fibrillation
Countries: France Health
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 90 results found since Jan 2013.
Management and outcomes of hypertrophic cardiomyopathy in young adults
CONCLUSIONS: In young adults with HCM, MACE are common in the short term, especially in obstructive HCM and women, mostly arrhythmic in origin. Prophylactic ICD implantation is frequent and does not strictly follow the guidelines, while the use of European/USA guidelines is helpful but imperfect in identifying SCD risk.PMID:33744178 | DOI:10.1016/j.acvd.2020.12.006
Source: Archives of Cardiovascular Diseases - March 21, 2021 Category: Cardiology Authors: Émilie Baron Nicole Karam Erwan Donal Tania Puscas Mariana Mirabel Anne Bacher Karim Wahbi Jean-Michael Mazzella Xavier Jeunemaitre Patricia Reant Albert Hag ège REMY, GEREMY working groups of the French Society of Cardiology Source Type: research
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research
